Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

Core Insights - Pliant Therapeutics will present three scientific posters at the 2025 American Thoracic Society (ATS) International Conference in San Francisco from May 16-21, 2025 [1][2]. Group 1: Presentations at ATS Conference - Pliant has been selected for a featured oral presentation at the ATS 2025 Mini Symposiums program [2]. - The oral presentation titled "Characterizing the Antifibrotic Activity of Bexotegrast on Distinct Fibroblast Populations in PCLS From Multiple ILD Subtypes" will be presented by Dr. Johanna Schaub on May 19, 2025, from 2:15 p.m. to 4:15 p.m. Pacific Time [3]. - Two posters will be presented on May 21, 2025, focusing on plasma proteome analysis and single-cell profiling related to antifibrotic effects of Bexotegrast, both scheduled from 8:15 a.m. to 10:15 a.m. Pacific Time [3]. Group 2: Company Overview - Pliant Therapeutics is a late-stage biopharmaceutical company specializing in novel therapeutics for fibrotic diseases [4]. - The lead product candidate, Bexotegrast (PLN-74809), is an oral small molecule targeting idiopathic pulmonary fibrosis (IPF) and has received Fast Track and Orphan Drug Designations from the FDA [4]. - Pliant is also developing PLN-101095 for solid tumors and has regulatory clearance for a Phase 1 study of PLN-101325 targeting muscular dystrophies [4].